44 results about "Synthetic protein" patented technology

The invention relates to the technical field of biology, in particular to a gene for increasing the content of resveratrol in grapes and application of the gene. The invention discloses a gene for improving the content of resveratrol in grapes. The DNA sequence of the gene is shown as SEQ ID NO1. The amino acid sequence of the gene synthetic protein disclosed by the invention is as shown in SEQ ID NO2, and the protein is named as VvFHY34D. According to the invention, when four amino acids S124, T128, S156 and T160 of the VvFHY3 are all replaced with aspartic acid to simulate phosphorylation activation, the VvSTS expression quantity in transient over-expression VvFHY34D grapes is higher, and more resveratrol can be synthesized.

Provided herein are methods for screening for and identifying insecticidal proteins along with recombinant nucleic acids, DNA constructs, vectors, fusion proteins, and spores useful in the provided methods. The provided methods enable effective, high throughput screening of candidate insecticidal proteins, including naturally occurring and engineered synthetic proteins.

The present disclosure relates to compositions and methods for treating disease. More particularly, the present disclosure relates to stable chimeric synthetic proteins and their use in treating cancer.

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

Disclosed herein include methods, compositions, and kits suitable for use in programmable cell death control. Compositions (e.g., nucleic acid compositions, synthetic protein circuits) provided herein can comprise one or more apoptosis polypeptides; and / or one or more pyroptosis polypeptides; and / or one or more input polypeptides. In some embodiments, expression of a synthetic protein circuit of the disclosure can induce, e.g., apoptosis and / or pyroptosis in a cell.

Recombinant E. coli strains and synthetic protein sequence designs are leveraged for production of disordered polypeptides such as spidroins and elastin-like peptides (ELPs). These disordered polypeptides, the high-titer production of which has proven difficult, include repeating structural motifs from a small selection of amino acid residues, resulting in lack of well-defined tertiary and quaternary structure. The recombinant E. coli include expression vectors with genes encoding for the disordered polypeptide product. Expression of these genes is controlled by a promoter that downregulates and substantially inhibits basal expression in the recombinant bacteria. Further, the recombinant bacteria include mutations to one or more stress-response genes from wild-type E. coli, such as yggw, yedv, yedw, yedy, spec, speb, uspc, hcha, loip, mltc, envz, ompr, yhgf, or hupb. The recombinant E. coli enable production of high titers of disordered protein product while minimizing the toxic effects thereof on the host.

A synthetic protein molecule includes a scaffolding framework and at least one ligand attached to the scaffolding framework. The scaffolding framework is selected for mimicking a conformation of a naturally occurring monomer protein. A plurality of the naturally occurring monomer protein so selected exhibit a tendency for aggregation thereof to form a plurality of oligomers. The at least one ligand is selected for an affinity for the plurality of oligomers so as to inhibit aggregation of the plurality of oligomers. An associated method for synthesizing a synthetic protein molecule is also disclosed. The synthetic protein molecule may be a foldamer.

The invention discloses a synthetic protein design method based on protein feature engineering and a diffusion model, which comprises the following steps: firstly, searching a homologous sequence of a query sequence in a non-redundant NR database by using a P-BLAST tool and taking a target protein sequence as the query sequence; carrying out ProtParam-7 and ProtFactor-5 feature engineering on the screened homologous sequences, and carrying out ProtParam-7 and ProtFactor-5 feature engineering on the screened homologous sequences; taking data represented by the ProtParam-7 and ProtFactor-5 characteristics as original proteins, and inputting the original proteins into the diffusion model; performing multi-dimensional screening on the generated candidate proteins; evaluating the functional activity and the structural stability of the candidate protein by adopting a wet experiment, and taking the protein meeting the condition as a final generation result. According to the method, protein sequence feature extraction and diffusion model generation are combined, and multi-dimensional screening and experimental verification are carried out to ensure that the generated protein is close to the target protein in structure and function.

The invention discloses a method for continuously manufacturing high-strength and high-toughness protein-like fibers, which comprises the following steps: S1, pumping a protein-like solution with the mass concentration of 15-25% to a spinning nozzle through a guide pipe, immersing the spinning nozzle into a coagulating bath solution, and forming protein-like fibrils in a coagulating bath; s2, collecting the protein-like fibrils by adopting a multistage roller collector through continuous differential stretching, wherein the differential stretching multiple is 2-10 times; and S3, putting the collected protein-like fibrils into a drying oven, and carrying out heating treatment at 90-190 DEG C for 10-120 minutes, so as to obtain the high-strength and high-toughness protein-like fibers. The mechanical property of the protein-like fiber prepared by the method is obviously better than that of natural fiber represented by silk and currently known synthetic protein fiber, and the application of the protein-like fiber in the high-tech fields such as biomedicine is developed; the method is simple in process and low in cost, does not involve large-scale change of existing equipment, and has a wide application prospect.

Presented herein are synthetic protein phosphorylation signaling networks.

Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a mutant Notch NRR (Negative Regulatory Region). Another aspect of the invention relates to a protease-dependent synthetic protein. Engineered cells comprising the synthetic protein are additionally described herein.

The present disclosure relates to stable chimeric synthetic proteins and therapeutic uses thereof. More particularly, the present disclosure relates to stable chimeric synthetic proteins and their use for the treatment of cancer.

A synthetic protein comprising: an N-terminal collagen-binding domain (CBD); a C-terminal C-type natriuretic peptide domain (CNP); and optionally, a spacer linking the CBD and the CNP.

A system is disclosed for de novo protein generation. The system receives a set of design condition(s) that specify target characteristics of a synthetic protein. The system defines a modular energy function as a composition of a diffusion energy component and one or more conditioner energy components. The system applies a diffusion model to determine a denoised protein backbone. In applying the diffusion model, in each sampling step: the system transforms one prior sampled state of the synthetic protein from unconstrained space into constrained space based on the one or more design conditions, denoises the prior sampled state in the constrained space, and samples a subsequent sampled stated by applying a gradient of the modular energy function to the denoised prior sampled state in the constrained space. The final sampled state is a denoised protein backbone for the synthetic protein that satisfies the set of design condition(s).

A synthetic protein switch is provided that has an active state and an inactive state and includes a C-terminal Src kinase (CSK) domain having an amino acid sequence that is at least 70% identical to, or a functional variant of, SEQ ID NO: 11 and a sensing domain, and wherein the synthetic protein switch reversibly converts from the inactive state to the active state upon interaction with an inducer and reversibly converts from the active state to the inactive state upon removal of the inducer. Also provided are methods for reversible modulation of T-cell signaling, treating a cytokine release syndrome (CRS), and treating a hematological malignancy using such synthetic protein switch. Further provided is a method of producing such synthetic protein switch, the method including transferring to a host cell or transfecting the host cell with a viral vector having a nucleic acid encoding the synthetic protein switch.

The disclosure relates to methods for treating cancer. More particularly, the disclosure relates to use of chimeric non-natural synthetic proteins, in combination with non-tyrosine targeting kinase inhibitors (NTKIs), in treating cancer and preventing intrinsic and / or acquired resistance to NTKIs.

The invention discloses a novel biological nano anti-mosquito drug based on iron-sulfur cluster synthetic protein as a target spot, belongs to the technical field of biological drugs, and develops a chitosan-sodium tripolyphosphate-dsNFS1 (CS-TPP-dsNFS1) biological nano anti-mosquito technology by taking AalbNFS1 as a target spot. A fluorescent quantitative PCR (polymerase chain reaction) method is used for detecting the expression level of tissue AalbNFS1 mRNA (messenger ribonucleic acid) at different time points after eclosion of aedes albopictus larvae fed with the CS-TPP-dsNFS1 nanoparticles. In addition, three days and four days after eclosion, the aedes albopictus fed with the CS-TPP-dsNFS1 nanoparticles are subjected to flight capability and blood sucking capability detection respectively, and then reproductive capability detection is performed. The result shows that the CS-TPP-dsNFS1 obviously inhibits the flying, blood sucking and reproductive capacities of aedes albopictus, which indicates that the CS-TPP-dsNFS1 taking the AalbNFS1 as the target spot is a novel developable anti-mosquito drug.

The invention belongs to the field of synthetic biology, and particularly relates to recombinant escherichia coli for producing ergothioneine and application of the recombinant escherichia coli. The recombinant Escherichia coli takes Escherichia coli BL21 (DE3) as a chassis strain, and heterologously expresses one or more of ergothioneine synthetic protein coding genes egtD, egtE and egt1T in the chassis strain. The capability of the engineering strain for synthesizing and producing ergothioneine from the beginning is verified through shake flask fermentation. In addition, through an optimal scheme, metabolic pathway transformation is carried out for synthesis precursors cysteine and S-adenosylmethionine of the ergothioneine, the yield of the ergothioneine is further increased, the yield can be increased by about 25% as compared with that of unmodified engineering bacteria, and the ergothioneine has a good application prospect of de novo synthesis and production of the ergothioneine.

The disclosed methods relate to a strategy for producing ground truth quantification ratios (both synthetic knockouts and simulated dose response gradients) using synthetic peptides mixed with a human proteome background. These, synthetic, bespoke proteins serve as a built in quality control for sample preparation for proteomics workflows. Additionally, mixtures of synthetic peptides are combined to form assembled synthetic proteins that can be spiked into samples at the start of processing (e.g., trypsin digesting, purification, etc.). In this way, problems in processing methods can be discovered. Sequences can be engineered to inform how well samples are being processed.

A system is disclosed for de novo protein generation. The system receives a set of design condition(s) that specify target characteristics of a synthetic protein. The system defines a modular energy function as a composition of a diffusion energy component and one or more conditioner energy components. The system applies a diffusion model to determine a denoised protein backbone. In applying the diffusion model, in each sampling step: the system transforms one prior sampled state of the synthetic protein from unconstrained space into constrained space based on the one or more design conditions, denoises the prior sampled state in the constrained space, and samples a subsequent sampled stated by applying a gradient of the modular energy function to the denoised prior sampled state in the constrained space. The final sampled state is a denoised protein backbone for the synthetic protein that satisfies the set of design condition(s).

Recombinant E. coli strains and synthetic protein sequence designs are leveraged for production of disordered polypeptides such as spidroins and elastin-like peptides (ELPs). These disordered polypeptides, the high-titer production of which has proven difficult, include repeating structural motifs from a small selection of amino acid residues, resulting in lack of well-defined tertiary and quaternary structure. The recombinant E. coli include expression vectors with genes encoding for the disordered polypeptide product. Expression of these genes is controlled by a promoter that downregulates and substantially inhibits basal expression in the recombinant bacteria. Further, the recombinant bacteria include mutations to one or more stress-response genes from wild-type E. coli, such as yggw, yedv, yedw, yedy, spec, speb, uspc, hcha, loip, mltc, envz, ompr, yhgf, or hupb. The recombinant E. coli enable production of high titers of disordered protein product while minimizing the toxic effects thereof on the host.

Provided herein are methods for screening and identifying pesticidal proteins, along with recombinant nucleic acids, DNA constructs, vectors, fusion proteins and spores useful in the provided methods. The provided methods allow for efficient high-throughput screening of candidate pesticidal proteins, including naturally occurring and engineered synthetic proteins.

The application discloses a synthetic protein design method based on protein feature engineering and diffusion model. First, a P-BLAST tool is used to search for homologous sequences of a query sequence in a non-redundant NR database by taking a target protein sequence as the query sequence; feature engineering is performed on the screened homologous sequences by using ProtParam-7 and ProtFactor-5; data represented by the ProtParam-7 and ProtFactor-5 features are taken as original protein input diffusion model; multidimensional screening is performed on the generated candidate proteins; wet experiments are adopted to evaluate the functional activity and structural stability of the candidate proteins, and proteins meeting the conditions are taken as the final generated results. The method combines protein sequence feature extraction and diffusion model generation, and through multidimensional screening and experimental verification, it is ensured that the generated protein is close to the target protein in structure and function.

The present invention discloses a method for synthetic protein dry screening based on a pre-trained model. First, a protein sequence is input into a pre-trained WGAN model to form a pre-trained generator; a Mask operation is performed on specific amino acids in the protein sequence, and the generator is used to imitate the target sequence to generate a batch of synthetic protein sequences; it is checked whether the solubility of the synthetic protein sequences is greater than 0.70 and whether the number of special amino acids exceeds the number of special amino acids in the target sequence plus 1; if the conditions are met, first calculate the backbone distance and the feature distance between the synthetic protein sequence and the target sequence, sort these two distances in ascending order respectively, and select the corresponding synthetic protein according to the sorting results as the final screening result. This method utilizes the comprehensive information of structural and physicochemical properties and can effectively predict and screen synthetic proteins that are more similar to the target sequence in terms of structure and physicochemical properties.

A method for synthesizing a synthetic molecule includes selecting a target protein, selecting a common precursor, providing first and second side-chains, forming a first monomer, including the common precursor and first side-chain, forming a second monomer, including the common precursor and second side-chain, evaluating the first and second monomers using an aggregation assay with the target protein to generate first results, and selecting one of the first and second monomers as a selected monomer based on the first results. Further, the method includes providing third and fourth monomers compatible with the selected monomer, forming a first dimer, including the selected monomer and third monomer, forming a second dimer, including the selected monomer and fourth monomer, evaluating the first and second dimers with the aggregation assay to generate second results, and selecting one of the first and second dimers as a selected dimer based on the second results.

To provide a simple approach to facilitate in vivo delivery and modifications of a biologic using advanced DNA / electroporation (EP) technology.SOLUTION: The present invention provides methods of post-translationally modifying a synthetic protein in a subject. In one embodiment, the method comprises administering to the subject a composition comprising a first recombinant nucleic acid sequence encoding the synthetic protein, and a second recombinant nucleic acid sequence encoding a modifier protein, the modifier protein post-translationally modifying the synthetic biologic in the subject. In one embodiment, the post translational modification is sulfation, and the modifier protein is selected from the group consisting of tyrosylprotein sulfotransferase 1 (TPST1) and TPST2.SELECTED DRAWING: Figure 1A

Disclosed herein include methods, compositions, and kits suitable for use in programmable cell death control. Compositions (e.g., nucleic acid compositions, synthetic protein circuits) provided herein can comprise one or more apoptosis polypeptides; and / or one or more pyroptosis polypeptides; and / or one or more input polypeptides. In some embodiments, expression of a synthetic protein circuit of the disclosure can induce, e.g., apoptosis and / or pyroptosis in a cell.

Described are non-animal protein blends comprising legume protein, and one or more of synthetic protein, seed protein, and grain protein, wherein the blend has a PDCAAS of 1. Compositions comprising these blends and methods of using them are also disclosed.

Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a mutant Notch NRR (Negative Regulatory Region). Another aspect of the invention relates to a protease-dependent synthetic protein. Engineered cells comprising the synthetic protein are additionally described herein.

A system is disclosed for de novo protein generation. The system receives a set of design condition(s) that specify target characteristics of a synthetic protein. The system defines a modular energy function as a composition of a diffusion energy component and one or more conditioner energy components. The system applies a diffusion model to determine a denoised protein backbone. In applying the diffusion model, in each sampling step: the system transforms one prior sampled state of the synthetic protein from unconstrained space into constrained space based on the one or more design conditions, denoises the prior sampled state in the constrained space, and samples a subsequent sampled stated by applying a gradient of the modular energy function to the denoised prior sampled state in the constrained space. The final sampled state is a denoised protein backbone for the synthetic protein that satisfies the set of design condition(s).